once it hits the market, page-22

i agree about blue sky potential, TDA. the company has been right to focus on getting our version of Fondaparinux to market, but currently that's out of our hands. one can therefore assume management are working on how to proceed with HyAct and specifically ha-irinotecan stage III trials. there is a huge amount of blue sky in ACL's stable. the announcement of a partnering deal regarding oncology drugs would put a rocket under the sp.

-j